Abstract
Comprehensive SummaryPlinabulin, a potential vascular disrupting agent (VDA), has entered the phase III clinical trial. However, the antitumor efficacy of Plinabulin is only moderate, which is probably because of the short action time of acting on tubulin. To maintain a constant VDAs concentration around the tumor vascular endothelial cells, in this study, we developed a novel Plinabulin derivate named HBP and further prepared noncovalent HBP nanoparticles (HBP NPs). We examined and compared the antitumor efficiency of HBP and HBP NPs in 4T1 tumor‐bearing mice. HBP NPs significantly increased therapeutic efficiency than HBP, even with a quarter dose. These findings exhibited in this paper further confirmed the opinion that VDAs nanomedicine could markedly enhance tumor therapeutic effect more than small molecular VDAs.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
